How to Help Your Patients Find Fintepla in Stock: A Provider's Guide

For patients with Dravet syndrome or Lennox-Gastaut syndrome, getting Fintepla (fenfluramine) in hand can be a months-long ordeal if the system isn't navigated efficiently. As the prescribing provider, your office's processes can make or break the timeline. This guide covers practical steps your team can take to streamline access for every patient.

Step 1: Confirm Your REMS Enrollment Is Active

The first bottleneck is prescriber REMS certification. If you haven't prescribed Fintepla before, or if your enrollment has lapsed, you must re-enroll at FinteplaREMS.com or by calling 1-877-964-3649. Enrolling typically takes 1-2 weeks. Your practice administrator can also manage multiple prescriber enrollments on your staff's behalf.

Once enrolled, you'll receive a prescriber certification number. This number must appear on all Fintepla prescriptions or they cannot be filled. Make sure your staff and EHR system are set up to include it automatically.

Step 2: Order and Document the Baseline Echocardiogram

A baseline echocardiogram must be completed before the patient's first dose. Order this at the decision visit, not after prescribing — even a 2-week wait for the echocardiogram can delay treatment significantly. Consider building same-day or next-day echo referral pathways into your practice workflow.

Some patients may be eligible for at-home echocardiogram services through the REMS program — particularly those with mobility limitations or living in rural areas. Ask the REMS team about this option. Document the echo results and include them in the prior authorization request.

Ongoing monitoring requirements: repeat echo every 6 months during treatment and once at 3-6 months post-treatment. Set up calendar reminders or care coordinator workflows so these don't slip.

Step 3: Submit a Strong Prior Authorization Request

Prior authorization is required by the vast majority of commercial and government payers. A robust initial PA submission dramatically reduces denials and shortens time to approval. Include the following in every PA request:

Diagnosis documentation: SCN1A genetic testing results (Dravet syndrome) or EEG and clinical criteria (LGS)

Seizure burden: Recent seizure diary showing frequency, type, and duration

Prior treatment failures: Full AED history with agents, doses, trial duration, and reason for discontinuation

REMS compliance plan: Baseline echocardiogram scheduled or completed; cardiac monitoring schedule

Clinical rationale: Letter of medical necessity citing FDA labeling, treatment guidelines, and the patient's specific clinical profile

Standard PA review takes 30-45 days. For urgent cases, request expedited review (typically 72 hours). If denied, appeal promptly — well-documented appeals often succeed.

Step 4: Connect Patients with the Right Specialty Pharmacy

Fintepla can only be dispensed through REMS-certified specialty pharmacies. When writing the prescription, direct it to a certified specialty pharmacy that is in-network for the patient's insurance. The FINTEPLA REMS program or UCB's ONWARD team can help identify in-network options.

For patients who need help identifying which specific specialty pharmacy location can fill their prescription, medfinder is a service that contacts pharmacies on their behalf. This can be especially useful for families who are time-constrained or dealing with the complexity of a new diagnosis.

Step 5: Brief Your Care Team on Ongoing Monitoring

Once patients are on Fintepla, the monitoring burden shifts to your practice. Establish clear workflows for:

Scheduling and tracking repeat echocardiograms every 6 months

Monitoring blood pressure at follow-up visits (hypertension is a known side effect)

Tracking weight and appetite — particularly in pediatric patients where growth monitoring is critical

Reviewing any new medications for serotonin syndrome risk (SSRIs, SNRIs, TCAs, MAOIs)

PA renewals — most insurers require annual re-authorization

Key Resources for Your Practice

FINTEPLA REMS program: FinteplaREMS.com | 1-877-964-3649

UCB ONWARD Patient Support: 1-833-463-7547 (PA support, copay assistance, pharmacy coordination)

FINTEPLA HCP site: finteplahcp.com (dosing guides, REMS enrollment, monitoring protocols)

medfinder for providers: [@portabletext/react] Unknown block type "span", specify a component for it in the `components.types` prop (pharmacy location and availability checks)

For a deeper dive into the clinical access landscape, read our Fintepla provider access guide for 2026.